Background-Prior small to modest-sized studies suggest a benefit of intravascular ultrasound (IVUS) guidance in noncomplex lesions. Whether IVUS guidance is associated with improved clinical outcomes after drug-eluting stent (DES) implantation in an unrestricted patient population is unknown. Methods and Results-Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) was a prospective, multicenter, nonrandomized "all-comers" study of 8583 consecutive patients at 11 international centers designed to determine the frequency, timing, and correlates of stent thrombosis and adverse clinical events after DES. Propensity-adjusted multivariable analysis was performed to examine the relationship between IVUS guidance and 1-year outcomes. IVUS was utilized in 3349 patients (39%), and larger-diameter devices, longer stents, and/or higher inflation pressures were used in 74% of IVUS-guided cases. IVUS guidance compared with angiography guidance was associated with reduced 1-year rates of definite/probable stent thrombosis (0.6% [18 events] versus 1.0% [53 events]; adjusted hazard radio, 0.40; 95% confidence interval, 0.21-0.73; P=0.003), myocardial infarction (2.5% versus 3.7%; adjusted hazard radio, 0.66; 95% confidence interval, 0.49-0.88; P=0.004), and composite adjudicated major adverse cardiac events (ie, cardiac death, myocardial infarction, or stent thrombosis) (3.1% versus 4.7%; adjusted hazard radio, 0.70; 95% confidence interval, 0.55-0.88; P=0.002). The benefits of IVUS were especially evident in patients with acute coronary syndromes and complex lesions, although significant reductions in major adverse cardiac events were present in all patient subgroups those with including stable angina and single-vessel disease. Conclusions-In ADAPT-DES, the largest study of IVUS use to date, IVUS guidance was associated with a reduction in stent thrombosis, myocardial infarction, and major adverse cardiac events within 1 year after DES implantation. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00638794.
I ntravascular ultrasound (IVUS) has been used for >2 decades to guide percutaneous coronary intervention (PCI) and is currently most frequently used to optimize stent expansion and apposition. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Nonetheless, definitive randomized trials to demonstrate whether IVUS guidance improves clinical outcomes after stent implantation have not been performed, with most prior trials being underpowered and restricted to noncomplex lesions. The benefits of IVUS after drug-eluting stent (DES) use are particularly controversial given the improved outcomes with DES compared with bare metal stents. This issue is especially important because stent thrombosis (ST) still occurs even with second-generation DES (especially in complex lesions) and is associated with high rates of myocardial infarction (MI) and mortality. 17, 18 A recent meta-analysis from 11 studies (only 1 of which was randomized) suggested that IVUS-guided DES implantation compared with angiographic guidance alone might reduce the incidence of death, ST, and major adverse cardiac events (MACE) but not MI or target vessel revascularization (TVR). However, most of the studies included in this meta-analysis were modest in size, and none reported how IVUS was used to actually guide the procedure. 19 The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) study was a large-scale, prospective, multicenter study designed to assess the relationship between platelet reactivity and other clinical and procedural variables with subsequent ST and adverse clinical events in patients treated with coronary DES. The present study reports a prespecified substudy from ADAPT-DES comparing the outcomes of IVUS guidance versus angiographic guidance of DES implantation.
Methods

Study Design and Protocol
The design, major inclusion and exclusion criteria, end points, and definitions from the ADAPT-DES study have been described in detail. 20 In brief, in the ADAPT-DES study, up to 11 000 consecutive patients at 11 US and German sites successfully treated with ≥1 Food and Drug Administration-or CE Mark-approved DES were eligible for enrollment, regardless of patient or lesion complexity. The only major exclusion criteria were the occurrence of a major complication during the procedure or before platelet function testing or planned bypass surgery after PCI. All patients were loaded with aspirin and clopidogrel. Platelet reactivity was assessed after successful PCI, usually on the morning after the procedure, with the use of the VerifyNow Aspirin, P2Y12, and IIb/IIIa assays (Accumetrics, San Diego, CA). 21 A prescribed washout period for glycoprotein IIb/IIIa inhibitors was required before platelet function testing. After PCI, patients were treated with aspirin indefinitely, and clopidogrel was recommended for at least 1 year. Clinical follow-up was scheduled at 30 days, 1 year, and 2 years by telephone contact. At the time of the present analysis, all patients had reached the 1-year follow-up period.
Procedural IVUS use was per operator discretion. When IVUS was used, the operator was required to report the timing of IVUS imaging (eg, before intervention, after DES, after adjunct balloon inflation) and how the IVUS information influenced the procedure. The study was approved by the institutional review board at each participating center, and all eligible patients signed written informed consent.
End Points and Definitions
Study monitors traveled at regular intervals to the enrolling sites to independently assess the accuracy of data entry and to collect original source documents in patients with adverse events. An independent committee of 3 physicians met routinely to adjudicate all deaths and MI and ST events, reviewing hospital charts, ECGs, coronary angiograms, and other data as required.
Clopidogrel hyporesponsiveness was defined as VerifyNow P2Y12 >208 platelet reaction units. Aspirin hyporesponsiveness was defined as VerifyNow aspirin ≥550 aspirin reaction units.
The primary end point was definite or probable ST according to the Academic Research Consortium definitions. 22 Additional end points included all-cause mortality, MI, revascularization, and major bleeding. Cardiac biomarkers were assessed before and after the procedure for evidence of adverse clinical events, according to the local standard of care. Periprocedural MI was defined as total creatine kinase (CK) >2 times the upper limit of normal with a positive CK-MB or troponin I or T. If the total CK was not available, then CK-MB >3 times the upper limit of normal was considered evidence of a periprocedural MI. If neither CK nor CK-MB was available, then troponin elevation >5 times the 99th percentile of the upper reference limit or upper limit of normal for the specific institution was considered evidence of periprocedural MI. MI unrelated to the PCI procedure was defined as (1) typical rise and fall of biochemical markers (troponin or CK-MB) of myocardial necrosis with either ischemic symptoms, development of new pathological Q waves, or ECG changes indicative of ischemia; (2) development of new pathological Q waves; or (3) pathological findings of an acute MI. ST, MI, and death were adjudicated by an independent clinical events committee using original source documents without knowledge of whether IVUS was used during the index procedure. Major bleeding was defined as a Thrombolysis in Myocardial Infarction (TIMI) major or minor bleed, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) bleed, and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) bleed or any postdischarge bleeding event requiring medical attention. Stroke was defined as an acute neurological deficit lasting >24 hours, as diagnosed by a physician, with supporting information, including brain imaging and neurological/neurosurgical evaluation. 23, 24 Ischemia-driven target lesion revascularization (TLR), TVR, major bleeding, and stroke were site reported but not centrally adjudicated.
Statistical Methods
As described previously, with an anticipated 1-year ST rate of 1.0%, a sample size of 11 000 patients was estimated to provide >99% power to identify variables associated with ST with a hazard ratio of >3. 20 Enrollment was terminated after 8665 patients were enrolled given financial considerations; this reduced sample size still provided 99% power. 20 Categorical variables were compared between groups by χ 2 or Fisher exact test. Continuous variables were presented as mean±SD and were compared between groups by Student t test. Time-to-event data are summarized as Kaplan-Meier estimates and were compared between groups with the log-rank test. Landmark analysis was used to determine the time-to-event rates from 0 to 30 days and >30 days to 1 year. A propensity score was constructed by modeling IVUS guidance in a logistic regression model with the following variables: age, gender, race, body mass index, current smoker, history of diabetes mellitus, insulin dependence, renal insufficiency, hemodialysis, hypertension, hyperlipidemia, peripheral artery disease, history of congestive heart failure, previous brachytherapy, prior MI, prior coronary artery bypass, Killip class at presentation, cardiac diagnosis, all medications preadmission through PCI, all laboratory data, hemodynamic support, access site, closure device, number of diseased vessels, number of lesions, number of stents, prediameter and postdiameter stenosis, prestent and final TIMI flow, maximum vessel diameter, calcium, ostial location, bifurcation, chronic total occlusion, total lesion and stent length, maximum device diameter, maximum balloon pressure, dissection, DES use only, stent type, and site. Then, to determine the predictors of outcomes, platelet reactivity plus other baseline variables considered clinically relevant were entered into multivariable Cox proportional hazards regression models stratified by the quintiles of the propensity score. The Supremum test verified that the proportional hazards assumption was valid for modeling both early and late ST (P=0.57 and P=0.13, respectively). A P value <0.05 was considered significant for all analyses. Statistical analyses were performed with the use of SAS version 9.1.3 (SAS Institute, Cary, NC). platelet function testing was performed before the protocolrequired glycoprotein IIb/IIIa inhibitor washout period. Thus, the final study population consisted of 8583 patients. IVUSguided stenting was performed in 3349 patients (39%), and angiography-guided stenting was performed in 5234 patients (61%). The follow-up rate at 1 year was 96%, including 97% with IVUS guidance versus 96% with angiography guidance (P=0.10).
Patient and Procedural Characteristics According to IVUS Use
Compared with patients stented with angiography guidance alone, those in whom IVUS was used were slightly younger, were more likely to be smokers, and more frequently presented with ST-segment elevation MI (STEMI) but were less likely to have hypertension, hyperlipidemia, and prior coronary artery bypass grafting ( Table 1 ). As shown in Table 2 , heparin was used more frequently and bivalirudin less frequently in the IVUS-guided group compared with the angiography-guided group. Clopidogrel hyporesponsiveness was also slightly more frequently observed in the IVUS-guided group, as was thienopyridine use at 1 year. Although 3-vessel disease was less common and fewer lesions per patient were treated in the IVUS-guided group, total stent length was longer than in the angiography-guided group (Table 3) . Everolimus-eluting stents and larger stents were more commonly used in the IVUS-guided group.
Procedural IVUS Use
In the IVUS-guided group, IVUS was used only before PCI in 7% of patients, only after PCI in 30% of patients, and both before and after PCI in 63% of patients. Solely on the basis of the IVUS evaluation, the operator changed the PCI strategy in 74% (2484/3349) of patients to choose (1) 
Clinical Outcomes
As shown in Table 4 , the unadjusted 1-year rate of definite/ probable ST was significantly lower in the IVUS-guided group compared with the angiography-guided group (0.6% [18 events] versus 1.0% [53 events]; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.31-0.90; P=0.017) (Figure, left). This difference was present within 1 month of stent implantation, with continued divergence of the curves apparent between 1 month and 1 year. Findings of both definite and probable ST were less in the IVUS-guided group.
The 1-year unadjusted rates of MI were also significantly lower in IVUS-guided compared with angiography-guided patients (2.5% versus 3.7%; HR, 0.67; 95% CI, 0.51-0.87; P=0.002) ( (Figure, right) . Rates of MACE were significantly lower with IVUS guidance in patients treated with complex disease (left main lesions, bifurcation lesions, and/or multivessel disease) as well as in those with noncomplex disease, although the absolute reduction in 1-year MACE was greater in complex patients ( Figure I in the online-only Data Supplement). Similarly, the absolute reduction in MACE was greatest in patients presenting with STEMI, intermediate in those with non-STEMI or unstable angina, and least (but still significantly lower) in those with stable angina ( Figure   II in the online-only Data Supplement). To examine potential causes for this gradient in effect, we compared the lesion characteristics among patients with STEMI, non-STEMI or unstable angina, and stable angina. Across the 3 groups, (1) STEMI lesions had the least prevalence of complex lesion morphology such as 3-vessel disease, calcification, bifurcation, in-stent restenosis, or left main disease; and (2) STEMI lesions showed the most prevalence of thrombus with prestent TIMI grade 0/1 and largest vessel size, but no difference was observed for the incidence of final TIMI grade 3 compared with the lesions in the patients with non-STEMI, unstable angina, or stable angina.
IVUS use varied across the 11 sites from <1% to 90% of cases (median, 33%). A total of 115 operators enrolled patients from the 11 sites, with the median IVUS use per operator ranging from 0% to 94.1% of cases. There was no significant interaction between IVUS guidance versus angiography guidance for the 1-year occurrence of the primary end point of definite/probable ST between the sites that used IVUS greater than versus less than the median (P for interac-tion=0.66). The multivariable predictors of IVUS use appear in Table I in the online-only Data Supplement. By propensity-adjusted multivariable analysis (which accounted for site, specific DES type, and other variables related to IVUS use), IVUS guidance was a predictor of definite/probable ST, MI, and MACE (Tables 5-7 ).
Discussion
The principal findings from this study are as follows: (1) Longer stent lengths and larger stent sizes were used in the IVUS-guided group compared with angiography guidance alone without increasing periprocedural MI; (2) IVUS guidance was strongly associated with lower 1-year rates of definite/probable DES thrombosis, MI, and MACE, as well as ischemic TLR and TVR; and (3) the greatest absolute benefits of IVUS-guidance were present in patients with acute coronary syndromes and complex coronary anatomy, although significantly better event-free survival was observed in all patient groups.
In prior randomized trials of IVUS-guided versus angiography-guided bare metal stent implantation, IVUS resulted in greater acute lumen gains with reductions in subsequent restenosis and repeat revascularization but not MI or mortality. 1 In the DES era, a meta-analysis including this trial and 10 registries reported that IVUS guidance may reduce ST and cardiac death after DES, although TVR rates were reduced only in complex lesion cohorts. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The present study reports by far the largest experience with IVUS guidance of DES implantation, with a major strength being enrollment of an all-comers population. In this population, IVUS guidance was associated with lower rates of ST, MI, and ischemia-driven TLR and TVR compared with angiography guidance alone. Moreover, whereas the event-free survival curves showed the greatest separation in the first month, the advantage of IVUS guidance was maintained and even increased at 1 year, a finding not seen in the earlier smaller studies. 12, 13 In the present study, although MACE rates were lower in all patient groups in which IVUS guidance was used, the greatest absolute benefit of IVUS was present in patients with acute coronary syndromes, with a gradient of effect from STEMI to non-STEMI/unstable angina to stable coronary artery disease. In the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) IVUS substudy, early ST after primary PCI in STEMI was associated with small luminal areas within the stent and/or at the stent edge because of stent underexpansion, thrombus protrusion, and/or edge dissection. 25 The present study suggests that IVUS may substantially improve outcomes in patients with STEMI. Similarly, greater absolute benefits of IVUS were present in patients undergoing DES implantation in complex or multiple lesions compared with noncomplex single lesions. This may explain in part why earlier modest-sized studies evaluating IVUS guidance versus angiography guidance in mostly noncomplex patients and lesions were negative.
The 60% reduction in the rate of DES ST with the use of IVUS guidance (after adjustment for baseline differences, including site and stent type) in the present report is notable. Previous studies have demonstrated that the strongest predictors of DES thrombosis and restenosis are stent underexpansion and reference segment disease (including edge dissections, large untreated plaque burden, and small lumen area). [26] [27] [28] In the present study, a larger stent or balloon and/or higher inflation pressures (that would have minimized underexpansion) were used in ≈60% of IVUS-guided procedures, and additional stents (that would have mitigated inflow/outflow issues) were used in ≈20% of patients. These responses are most likely responsible for the lower rates of ST and clinical restenosis (TLR and TVR) observed in the IVUS cohort in the present study.
The 1-year rates of ST and MI, however, were significantly lower in the IVUS-guided group. Of note, the principal reduction in MI with IVUS was adjudicated to spontaneously occurring MIs and not to events related to either the procedure itself or ST. Although further study is required to understand the mechanisms through which IVUS reduced spontaneous MIs in the present study, identification and treatment of angiographically unapparent high-risk plaques adjacent to and in the same vessel as the stented segment may have contributed. In addition, in-stent restenosis may present as acute MI in 4% to 10% of cases, 29, 30 and procedures for restenosis may result in MI. Reducing TLR and TVR with IVUS may thereby have also contributed to preventing subsequent MIs.
Of note, although larger stents and balloons, longer stents, and/or higher inflation pressures were used in 74.2% of IVUS-guided patients, the rate of periprocedural MI was not increased in the IVUS group. In contrast, in the randomized Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) trial of everolimus-versus sirolimus-eluting stents, IVUS was used in 619 patients (43.6%) and was associated with a significantly higher rate of periprocedural MIs compared with angiography guidance alone. 10 A sensitive definition of periprocedural MI (troponin >3 times normal, as suggested in the second universal definition of MI) was used in EXCELLENT, whereas the 
Study Limitations
The present study, although the largest to date examining the potential utility of IVUS guidance during stenting, was not a randomized trial. The decisions of whether to use IVUS and how to respond to the IVUS images were left to each operator's discretion, with no specific guidelines for optimal stenting. There was modest variation between the IVUS-guided versus angiography-guided patients; however, differences in clinical outcomes favoring IVUS persisted after propensityadjusted multivariable analysis. Nonetheless, possible bias from unmeasured confounders cannot be excluded. The results of the present report should thus be considered hypothesis generating. The present study also cannot determine which procedural choices that IVUS influenced (eg, larger devices, longer stents) were associated with improved outcomes. Routine core laboratory analysis was not performed, and thus we cannot determine the exact differences in stent expansion and other parameters that resulted from IVUS use. Moreover, IVUS was not performed in the control arm. Because angiographic changes in diameter often underestimate differences in minimal stent area, the modest increase in postprocedural luminal dimensions in the IVUS group likely underestimated the improvement in stent expansion in the IVUS-guided arm. Cardiac biomarkers were assessed after PCI only for evident adverse clinical events. As such, asymptomatic MIs may not have been detected, although given the fact that the present protocol excluded patients with major angiographic complications and unsuccessful procedures, it is unlikely that such occurrences would be prognostically relevant. 31 Finally, TVR, TLR, stroke, and bleeding events were not adjudicated by an independent clinical events committee, and thus we focused most of our analysis on ST, MI, and MACE.
Conclusions
The present study, drawn from the largest prospective study of IVUS use to date, suggests that IVUS guidance may reduce the rates of ST and MI within 1 year after DES implantation, with the greatest benefits present in patients with acute coronary syndromes and complex target lesions. 
